Larimar Therapeutics (LRMR) Earnings Date & Reports

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

LRMR is expected to report earnings to fall 22.98% to -34 cents per share on May 08

Larimar Therapeutics LRMR Stock Earnings Reports

Q1'25

Est.

$-0.35

Q4'24

Missed

by $0.14

Q3'24

Beat

by $0.13

Q2'24

Missed

by $0.03

Q1'24

Missed

by $0.03

The last earnings report on March 24 showed earnings per share of -44 cents, missing the estimate of -31 cents. With 1.42M shares outstanding, the current market capitalization sits at 152.39M.

View a ticker or compare two or three

Compare

LRMR

Setup

Buy or SellView

Daily Signalchanged days ago

Gain/Loss if bought

View Trends For LRMR
(Try 14 days for Free)

Ad is loading...

A.I.Advisor

published price charts

A.I. Advisor

published General Information

General Information

a clinical-stage biopharmaceutical company, which engages in the research and development of a therapeutic treatment for mitochondrial disorders and Friedreich's ataxia

Industry Biotechnology

Profile

Fundamentals

Details

Industry

N/A

Address

Three Bala Plaza East

Phone

+1 844 511-9056

Employees

Web

https://www.larimartx.com